Breast Cancer: Targets and Therapy
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
(6162) Total Article Views
Authors: Menis J, Twelves C
Published Date August 2011
Volume 2011:3 Pages 101 - 111
J Menis1, C Twelves2
1Department of Oncology, University Hospital Santa Maria della Misericordia, Udine, Italy; 2Leeds Cancer Research UK Centre, University of Leeds and St James's Institute of Oncology, Leeds, UK
Abstract: Although metastatic breast cancer remains essentially incurable, many patients previously treated with an anthracycline, taxane, and capecitabine are relatively fit and keen to receive further therapy. Several drugs are used in this setting, but with little evidence of clinically relevant benefit, and none have previously shown improved survival. Eribulin (Halaven®) is a nontaxane tubulin-binding agent with a novel mode of action, and was recently approved by the European Medicines Agency and US Food and Drug Agency as a single agent for patients with heavily pretreated metastatic breast cancer. This review provides an overview of the discovery, and preclinical and clinical development of eribulin, culminating in the recently published EMBRACE metastatic breast cancer study.
Keywords: eribulin, metastatic breast cancer, pretreated
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- MLA'14 -
May 16–21, 2014
- Cancer Pharmacogenomics and Targeted Therapies
17 - 19 September, 2014
- ESMO 2014 Congress
26 - 30 September, 2014
- The bradykinin B2 receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines
- Serous endometrial intraepithelial carcinoma: a case series and literature review
- Epigenomics in cancer management
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation